Nephron Research Initiates Formal Research Coverage of Brookdale Senior Living, Inc. (BKD)

Title: Path to Sanity is Through Operations 

A hallmark of Nephron’s independent model is our flexibility to focus on topics, sub-sectors, and stocks most relevant to our clients as well as those where we see the most opportunity from an investment perspective.  With a focus on the latter, Josh Raskin and team initiated coverage of Brookdale Senior Living, Inc. (BKD) yesterday evening with a Buy rating and a $16 target. This represents the highest absolute return opportunity across our coverage universe.

Yesterday’s initiation included: 

  • A truly differentiated look at Brookdale away from recent events, emphasizing a fundamental case for ownership.
  • A call for investor attention at a time when such interest is low.
  • A 65-page companion report covering the investment case, industry fundamentals and a company overview.

With several significant changes in management, operations, portfolio and investor base, we think the timing is right to focus on Brookdale now, a change since we launched broader research coverage last December.

This is just one example of the kind of research product and coverage we think is lacking in the market today.  Nephron Research was formed with the simple thesis that an independent research entity will be able to provide a better research product. For platform access, email:

Please Note: The statements made are true as of the time of this post and Nephron makes no representation that any update will be provided to the viewer. For further information contact us regarding access to our platform and research. Investment decisions should not be made based on this information alone and the reader is encouraged to do further research